ANTIGEN-BINDING MOLECULES AGAINST ALPPL2 AND/OR ALPP AND USES THEREOF

The invention relates to antigen-binding molecules that specifically binds ALPPL2 and/or ALPP but not ALPL or ALPI. It also relates to a pharmaceutical composition, an immunoconjugate and a chimeric antigen receptor comprising said antigen-binding molecules. The invention also relates to methods for...

Full description

Saved in:
Bibliographic Details
Main Authors TAN, Boon Ooi Patrick, YAP, Thai Leong, WANG, Cheng-I, WAN, Kah Fei, SUN, William, LEE, Shuet Theng, HUANG, Ching-Wen, NG, Jian Duan Johnathan, WANG, Huajing, HONG, Shin Yee
Format Patent
LanguageEnglish
French
Published 12.08.2021
Subjects
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES
MEASURING
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PHYSICS
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
TESTING
Online AccessGet full text

Cover

More Information
Summary:The invention relates to antigen-binding molecules that specifically binds ALPPL2 and/or ALPP but not ALPL or ALPI. It also relates to a pharmaceutical composition, an immunoconjugate and a chimeric antigen receptor comprising said antigen-binding molecules. The invention also relates to methods for reducing the expression or activity of ALPPL2 in a cancer cell and methods of treating a cancer in a subject. L'invention concerne des molécules de liaison à l'antigène qui se lient de manière spécifique à ALPPL2 et/ou ALPP mais pas à ALPL ou ALPI. L'invention concerne également une composition pharmaceutique, un immunoconjugué et un récepteur d'antigène chimère comprenant lesdites molécules de liaison à l'antigène. L'invention concerne en outre des procédés de réduction de l'expression ou de l'activité de ALPPL2 dans une cellule cancéreuse et des méthodes de traitement d'un cancer chez un sujet.
Bibliography:Application Number: WO2021SG50061